Cardiac Biomarkers, Intensive Lifestyle Intervention, and Heart Failure Subtypes in Diabetes
Zainali Chunawala(Southwestern Medical Center), Ambarish Pandey(The University of Texas Southwestern Medical Center), Deepak L. Bhatt(Brigham and Women's Hospital), Antoni Bayés‐Genís(Universitat Autònoma de Barcelona), Rodica Pop‐Busui(University of Michigan), Javed Butler(University of Mississippi Medical Center), Kershaw V. Patel(Houston Methodist), Alain G. Bertoni(Wake Forest University), Mark A. Espeland(Wake Forest University), Subodh Verma(University of Toronto), Carolyn Lam(National University of Singapore), Katelyn R Garcia(Wake Forest University), James L. Januzzi(Harvard University), Matthew W. Segar
Cited by 1
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
|New England Journal of Medicine|2018|3.2k